GSK and other firms offer Bush help to fight avian flu pandemic

Share this article:

GlaxoSmithKline said it plans to double its vaccine production and other drug makers have offered their help during a meeting with President Bush last week as part of the administration's latest effort in preparing for the possibility of an avian flu pandemic.
GSK said it plans to double its annual flu vaccine production of 35 million doses in the coming years, according to a report from CNN/Money's Web site. GSK recently stepped up its flu manufacturing capacity by investing an additional $2 billion and ramping up production of antiviral vaccine Relenza.
"We have been working with the U.S. government, as well as governments and health authorities around the world, to outline our antiviral and flu vaccine capabilities, and identify how they fit into preparations for pandemic flu," GSK chief executive Jean-Pierre Garnier told reporters after a Friday meeting with President Bush.
Bush also met with Merck chief executive Richard Clark, Wyeth chief executive Robert Essner, MedImmune chief executive David Mott, Chiron chief executive Howard Pien and David Williams senior vice president of vaccines at Sanofi-Aventis subsidiary Aventis Pasteur.
Ian Spatz, vice president of public policy for Merck, told CNN/Money that Clark pledged to help Bush, even though the company does not produce the flu vaccine. Spatz said Merck would help to package the bulk vaccine, produced by another company, into a form that could be injected into patients.
And Wyeth spokesperson Doug Petkus said his company was prepared to answer the needs of the government in any way it could despite the fact that it does not make the flu vaccine. Petkus said Wyeth demonstrated this following the terror attacks of Sept. 11, 2001 when the company produced 10 million doses of smallpox vaccine at the government's request.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.